67237-63-2

Upstream product

• 1798-09-0 m-methoxyphenylacetic acid 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 4230-93-7 1,2-dimethoxy-4-(2-nitro-vinyl)-benzene 
• 221354-48-9 2-<3-methoxyphenyl>-1-tetrahydro-2H-1,4-oxazin-4-yl-1-ethanethione 

Downstream Products

• 608141-10-2 6,7-dimethoxy-1-(3'-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 109808-84-6 1-(3-methoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 67237-66-5 (R*,S*)-6,7-dimethoxy-1-[(3-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium chloride 
• 1443828-62-3 ((3-bromophenyl)(6,7-dimethoxy-1-(3-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone) 
• 1443828-61-2 ((3-chlorophenyl)(6,7-dimethoxy-1-(3-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone) 

Relevant academic research and scientific papers

Enantioselective Oxidative Aerobic Dealkylation of N-Ethyl Benzylisoquinolines by Employing the Berberine Bridge Enzyme

N-Dealkylation methods are well described for organic chemistry and the reaction is known in nature and drug metabolism; however, to our knowledge, enantioselective N-dealkylation has not been yet reported. In this study, exclusively the (S)-enantiomers o

Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D 1 receptor

A series of new tetrahydroprotoberberine (THPB) derivatives were designed, synthesized, and tested for their binding affinity towards dopamine (D 1 and D2) and serotonin (5-HT1A and 5-HT 2A) receptors. Many of the THPB compounds exhibited high binding affinity and activity at the dopamine D1 receptor, as well as high selectivity for the D1 receptor over the D2, 5-HT 1A, and 5-HT2A receptors. Among these, compound 19c exhibited a promising D1 receptor binding affinity (Ki = 2.53 nM) and remarkable selectivity versus D2R (inhibition = 81.87%), 5-HT1AR (inhibition = 61.70%), and 5-HT2AR (inhibition = 24.96%). Compared with l-(S)-stepholidine (l-SPD) (D1 Ki = 6.23 nM, D2 Ki = 56.17 nM), compound 19c showed better binding affinity for the D1 receptor (2.5-fold higher) and excellent D2/D1 selectivity. Functional assays found compounds 18j, 18k, and 19c are pure D1 receptor antagonists. These results indicate that removing the C10 hydroxy group and introducing a methoxy group at C11 of the pharmacophore of l-SPD can reverse the function of THPB compounds at the D1 receptor. These results are in accord with molecular docking studies.

TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compound

Antiplatelet activity of synthetic pyrrolo-benzylisoquinolines

Pyrrolo-benzylisoquinolines were prepared as target compounds and their antiplatelet aggregation activity, adreno-receptor affinity, and cytotoxicity were screened. Compounds 1d-9d showed specific antiplatelet aggregation activity induced by arachidonic acid and collagen. Among them, 8d and 9d exhibited better activity than the reference drug, aspirin and 9d also showed inhibition of platelet aggregation by all four inducers.